Journal
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
Volume 14, Issue -, Pages -Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/17588359221086916
Keywords
antibody-drug conjugates; emerging therapies; immunotherapy; metastatic triple-negative breast cancer
Categories
Ask authors/readers for more resources
This review article discusses novel treatment strategies for metastatic triple-negative breast cancer (mTNBC), including immune checkpoint inhibitors, targeted therapies, and antibody-drug conjugates. The article summarizes important preclinical and clinical data, discusses implications for clinical practice, and highlights future research directions.
Triple-negative breast cancer (TNBC) is a heterogeneous subtype of breast cancer that is often associated with an aggressive phenotype and a poor prognosis. Cytotoxic chemotherapy remains the mainstay of treatment for most patients with metastatic TNBC (mTNBC), but duration of response is often short and median overall survival is only 12-18 months. Therefore, it is critical to identify novel treatment strategies to improve outcomes for these patients. In this review article, we discuss recent advances in treatment strategies for patients with mTNBC including the use of immune checkpoint inhibitors, targeted therapies, and antibody-drug conjugates. For each topic, we summarize important preclinical and clinical data, discuss implications for clinical practice, and highlight future research directions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available